Dr. Marty Makary, President Trump’s nominee for the Food and Drug Administration (FDA) leadership, faces Senate questioning regarding his plans for the agency. Makary, a surgeon and researcher with unconventional views, aims to address health issues stemming from food additives, overprescribed drugs, and industry influences. His confirmation as FDA commissioner hinges on Senate approval following the committee’s questioning. Makary’s stance aligns with Republicans, advocating for a review of vaccine and drug safety, contrasting with Democratic concerns about childhood vaccinations. Despite past criticism of the FDA’s handling of COVID-19, Makary is deemed a conventional nominee and likely to secure confirmation.

Amidst leadership changes, the FDA grapples with internal turmoil, including recent layoffs and rehirings, senior official departures, and impending staff reductions. Makary’s potential appointment comes at a turbulent time for the agency, with challenges such as pressure from anti-abortion groups, adapting to AI-based medical systems, and legal disputes over off-brand weight-loss drugs. In light of potential conflicts of interest, Makary has severed ties with companies that may be affected by his FDA role. As the FDA oversees a wide range of products and faces multifaceted challenges, Makary’s leadership may shape the agency’s response to evolving regulatory and public health demands.